Olanzapine May Inhibit Colonic Motility Associated with the 5-HT Receptor and Myosin Light Chain Kinase
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
ObjectiveaaTo study whether the effects of olanzapine on gastrointestinal motility is related to the serotonin antagonism and myosin light chain kinase. MethodsaaMale Sprague-Dawley rats were randomly divided into four groups. Olanzapine gavage was performed for each treatment group during the course of 30 continuous days, while the same volume of saline was given to the rats in the control group. Defecation of the rats was observed on days 7 and 30 after olanzapine gavage. The effects of olanzapine on contraction of colonic smooth muscles were observed in ex vivo experiments. A Western blot was used to evaluate expression levels of the serotonin transporter (SERT) and MLCK in colon segments of the rats. ResultsaaCompared to the control group, 5–160 μM of olanzapine could inhibit dose-dependently the contraction of colonic smooth muscle ex vivo experiments. The maximum smooth muscle contraction effects of 5-HT and acetylcholine significantly decreased after treatment with 40–160 μM of olanzapine. Constipation was found in the olanzapine-treated rats on day 7 and have sustained day 30 after gavage. Expression of MLCK in olanzapine-treated rats was significantly decreased, whereas the expression of SERT significantly increased on the day 7, then significantly decreased on the day 30 after olanzapine gavage. ConclusionaaSERT and MLCK may involve in the inhibition of colonic contraction induced by olanzapine.
Abstract
ObjectiveaaTo study whether the effects of olanzapine on gastrointestinal motility is related to the serotonin antagonism and myosin light chain kinase. MethodsaaMale Sprague-Dawley rats were randomly divided into four groups. Olanzapine gavage was performed for each treatment group during the course of 30 continuous days, while the same volume of saline was given to the rats in the control group. Defecation of the rats was observed on days 7 and 30 after olanzapine gavage. The effects of olanzapine on contraction of colonic smooth muscles were observed in ex vivo experiments. A Western blot was used to evaluate expression levels of the serotonin transporter (SERT) and MLCK in colon segments of the rats. ResultsaaCompared to the control group, 5–160 μM of olanzapine could inhibit dose-dependently the contraction of colonic smooth muscle ex vivo experiments. The maximum smooth muscle contraction effects of 5-HT and acetylcholine significantly decreased after treatment with 40–160 μM of olanzapine. Constipation was found in the olanzapine-treated rats on day 7 and have sustained day 30 after gavage. Expression of MLCK in olanzapine-treated rats was significantly decreased, whereas the expression of SERT significantly increased on the day 7, then significantly decreased on the day 30 after olanzapine gavage. ConclusionaaSERT and MLCK may involve in the inhibition of colonic contraction induced by olanzapine.
참고문헌 (31)
- Prommer E, "Olanzapine : palliative medicine update", Am J Hosp Palliat Care, 30, pp.75~82 (2013)
- Kelly DL, "Plasma concentrations of high-dose olanzapine in a double-blind crossover study", Hum Psychopharmacol, 21, pp.393~398 (2006)
- Chew ML, "A model of anticholinergic activity of atypical antipsychotic medications", Schizophr Res, 88, pp.63~72 (2006)
- Rege S, "Life-threatening constipation associated with clozapine", Australas Psychiatry, 16, pp.216~219 (2008)
- Bymaster FP, "Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro", Schizophr Res, 37, pp.107~122 (1999)
- Bymaster FP, "In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug", J Clin Psychiatry, 58(Suppl 10), pp.28~36 (1997)
- Bhana N, "Olanzapine : an updated review of its use in the management of schizophrenia", Drugs, 61, pp.111~161 (2001)
- Kim DY, "Serotonin : a mediator of the brain-gut connection", Am J Gastroenterol, 95, pp.2698~2709 (2000)
- Tamir H, "Human serotonectin : a blood glycoprotein that binds serotonin and is associated with platelets and white blood cells", J Cell Sci, 73, pp.187~206 (1985)
- Sikander A, "Role of serotonin in gastrointestinal motility and irritable bowel syndrome", Clin Chim Acta, 403, pp.47~55 (2009)
- Bymaster FP, "Potent antagonism of 5-HT(3)and 5-HT(6)receptors by olanzapine", Eur J Pharmacol, 430, pp.341~349 (2001)
- Stasi C, "Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome", Tech Coloproctol, 18, pp.613~621 (2014)
- Kerckhoffs AP, "Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients", Neurogastroenterol Motil, 20, pp.900~907 (2008)
- Coates MD, "Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome", Gastroenterology, 126, pp.1657~1664 (2004)
- Costedio MM, "Serotonin and its role in colonic function and in gastrointestinal disorders", Dis Colon Rectum, 50, pp.376~388 (2007)
- He WQ, "Myosin light chain kinase is central to smooth muscle contraction and required for gastrointestinal motility in mice", Gastroenterology, 135, pp.610~620 (2008)
- Murthy KS, "Signaling for contraction and relaxation in smooth muscle of the gut", Annu Rev Physiol, 68, pp.345~374 (2006)
- Hu W, "Myosin light chain kinase is involved in the mechanism of gastrointestinal dysfunction in diabetic rats", Dig Dis Sci, 57, pp.1197~1202 (2012)
- Umer A, "The contractile effects of several substituted short analogues of porcine galanin in isolated rat jejunal and colonic smooth muscle strips", Pharmacol Res, 52, pp.283~289 (2005)
- Yong-jian Xiong, "The characteristics of genistin-induced inhibitory effects on intestinal motility", Archives of Pharmacal Research, 36(3), pp.345~352 (2013), 대한약학회
- Bymaster FP, "Muscarinic mechanisms of antipsychotic atypicality", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1125~1143 (2003)
- Farthing MJ, "Irritable bowel syndrome : new pharmaceutical approaches to treatment", Baillieres Best Pract Res Clin Gastroenterol, 13, pp.461~471 (1999)
- Wade PR, "Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract", J Neurosci, 16, pp.2352~2364 (1996)
- Spiller R, "Serotonin and GI clinical disorders", Neuropharmacology, 55, pp.1072~1080 (2008)
- Atkinson W, "Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome", Gastroenterology, 130, pp.34~43 (2006)
- Derkach V, "5-HT3 receptors are membrane ion channels", Nature, 339, pp.706~709 (1989)
- Guarino M, "Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation", Neurogastroenterol Motil, 23, pp.e575~e210 (2011)
- Costedio MM, "Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation", Am J Gastroenterol, 105, pp.1173~1180 (2010)
- Gustafsen J, "Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial", Scand J Gastroenterol, 21, pp.816~818 (1986)
- Kawamura H, "Inhibitory effect of chlorpromazine on RANKL-induced osteoclastogenesis in mouse bone marrow cells", J Pharmacol Sci, 117, pp.54~62 (2011)
- Gonzalez-Andrade M, "Importance of the interaction protein-protein of the CaM-PDE1A and CaM-MLCK complexes in the development of new anti-CaM drugs", J Mol Recognit, 26, pp.165~174 (2013)